News & Updates
Filter by Specialty:
Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients
Treatment with the glucagon-like peptide-1 (GLP-1)/glucagon receptor co-agonist efinopegdutide results in a greater decrease in liver fat content (LFC) relative to the GLP-1 receptor agonist semaglutide in patients with nonalcoholic fatty liver disease (NAFLD), results of a phase IIa trial have shown.
Efinopegdutide beats semaglutide at reducing liver fat in NAFLD patients
03 Oct 2023
Response to nucleos(t)ide analogues for hepatitis B higher among men vs women
Treatment outcomes with nucleos(t)ide analogues for hepatitis B patients appear to differ by sex, such that men are more likely to have biochemical response and achieve clinical remission than women, a study has shown.
Response to nucleos(t)ide analogues for hepatitis B higher among men vs women
25 Sep 2023
Liver transplant confers better long-term survival in select CRC patients
In the treatment of patients with nonresectable colorectal cancer (CRC) with liver metastases, liver transplantation may improve long-term survival outcomes especially when performed for those with favourable prognostic scoring, according to a study.
Liver transplant confers better long-term survival in select CRC patients
19 Sep 2023
Bulevirtide boasts high barrier to resistance for chronic hepatitis delta
A recent study has found no amino acid substitutions associated with reduced sensitivity to bulevirtide (BLV) monotherapy, a hepatitis D/B virus (HDV/HBV) entry inhibitor, at baseline or week 24 in patients with virologic breakthrough after BLV treatment.
Bulevirtide boasts high barrier to resistance for chronic hepatitis delta
13 Sep 2023
Noninvasive MRE accurately stages liver fibrosis in NAFLD
Magnetic resonance elastography demonstrates high accuracy in the noninvasive staging of liver fibrosis in patients with nonalcoholic fatty liver disease (NAFLD), reports a study.
